• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HER-2/neu、表皮生长因子受体及类固醇受体在正常和恶性子宫内膜中表达的免疫组织化学研究

Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.

作者信息

Bigsby R M, Li A X, Bomalaski J, Stehman F B, Look K Y, Sutton G P

机构信息

Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis.

出版信息

Obstet Gynecol. 1992 Jan;79(1):95-100.

PMID:1345772
Abstract

HER-2/neu oncogene protein, epidermal growth factor receptor, progesterone receptor, and estrogen receptor were examined immunohistochemically in specimens of normal and neoplastic endometrium. Tissues obtained at the time of hysterectomy were snap-frozen at liquid nitrogen temperature and serially sectioned at 4 microns. Normal endometrial epithelial cells stained with anti-epidermal growth factor receptor and anti-HER-2/neu with intensities graded from 0 to 3+. Of the 49 endometrial malignancies studied, seven (14%) contained tissue exhibiting HER-2/neu staining in excess (4+) of any of the normal tissues or the other 42 cancer specimens. Expression of both HER-2/neu and steroid receptors was heterogeneous within these seven tumors. To examine this heterogeneity more closely, sections of these and other tumors were double-stained for HER-2/neu and progesterone receptor. It was found that the cells exhibiting 4+ HER-2/neu staining were progesterone receptor-negative. Conversely, cells that were progesterone receptor-positive within the same specimen exhibited HER-2/neu immunostaining equal to or less than 3+. All specimens containing 4+ HER-2/neu tissue were graded 1 or 2 adenocarcinomas, stage I. Thus, there is an inverse relationship between overexpression of HER-2/neu and progesterone receptor in endometrial cancer. On the other hand, overexpression of HER-2/neu in endometrial cancer does not seem to be related to loss of other differentiated characteristics. The prognostic value of these observations awaits continued study.

摘要

采用免疫组织化学方法检测了正常及肿瘤性子宫内膜标本中的HER-2/neu癌基因蛋白、表皮生长因子受体、孕激素受体和雌激素受体。子宫切除时获取的组织在液氮温度下速冻,并切成4微米厚的连续切片。正常子宫内膜上皮细胞用抗表皮生长因子受体和抗HER-2/neu染色,强度从0到3+分级。在研究的49例子宫内膜恶性肿瘤中,有7例(14%)的组织中HER-2/neu染色强度超过任何正常组织或其他42例癌症标本(4+)。在这7例肿瘤中,HER-2/neu和类固醇受体的表达均呈异质性。为了更仔细地研究这种异质性,对这些肿瘤和其他肿瘤的切片进行了HER-2/neu和孕激素受体的双重染色。结果发现,HER-2/neu染色为4+的细胞孕激素受体阴性。相反,同一标本中孕激素受体阳性的细胞HER-2/neu免疫染色等于或小于3+。所有含有HER-2/neu组织4+的标本均为1级或2级腺癌,I期。因此,子宫内膜癌中HER-2/neu的过表达与孕激素受体之间存在负相关。另一方面,子宫内膜癌中HER-2/neu的过表达似乎与其他分化特征的丧失无关。这些观察结果的预后价值有待进一步研究。

相似文献

1
Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.HER-2/neu、表皮生长因子受体及类固醇受体在正常和恶性子宫内膜中表达的免疫组织化学研究
Obstet Gynecol. 1992 Jan;79(1):95-100.
2
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.Her-2/neu在淋巴结阴性乳腺癌中的表达:通过计算机图像分析进行直接组织定量以及过表达与疾病复发风险增加的关联
Cancer Res. 1993 Oct 15;53(20):4960-70.
3
Expression of HER-2/neu oncogene in normal, hyperplastic, and malignant endometrium.
Ann Clin Lab Sci. 1998 May-Jun;28(3):138-43.
4
The role of the HER-2/neu oncogene in gynecologic cancers.HER-2/neu癌基因在妇科癌症中的作用。
J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105.
5
Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.表皮生长因子受体(EGFR)、人表皮生长因子受体2(HER-2/neu)、P53和增殖细胞核抗原(PCNA)在子宫内膜样癌、浆液性乳头状癌和透明细胞子宫内膜腺癌中的表达
Gynecol Oncol. 1994 Apr;53(1):84-92. doi: 10.1006/gyno.1994.1092.
6
Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.HER-2/neu癌蛋白与表皮生长因子受体的表达及胃癌的预后
Arch Pathol Lab Med. 1994 Mar;118(3):235-9.
7
Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.神经分化因子/神经调节蛋白及其受体复合物在前列腺癌中的组织表达及其对前列腺癌细胞的体外生物学效应
Cancer J Sci Am. 1997 Jan-Feb;3(1):21-30.
8
Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.转移相关基因nm23-H1和nm23-H2在卵巢癌中的表达:与临床病理、表皮生长因子受体(EGFR)、原癌基因c-erbB-2和c-erbB-3以及性甾体激素受体表达的相关性
Cancer Res. 1994 Apr 1;54(7):1825-30.
9
Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.环氧化酶-2(COX-2)、雌激素受体(ER)、孕激素受体(PR)、p53、ki67及neu蛋白在子宫内膜癌中的表达
Gynecol Oncol. 2005 Sep;98(3):383-9. doi: 10.1016/j.ygyno.2005.04.024.
10
Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.人乳腺癌中表皮生长因子受体、Her-2/neu和p21ras的细胞内共表达:不同患者肿瘤中存在共同的独特遗传进化模式的证据。
Clin Cancer Res. 1998 Apr;4(4):913-28.

引用本文的文献

1
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.妇科癌症生物标志物驱动疗法的合理选择:我们知道得越多,就越清楚自己未知的越多。
Gynecol Oncol. 2016 Apr;141(1):65-71. doi: 10.1016/j.ygyno.2016.01.003.
2
Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.EGFR/HER 受体的综合分析用于妇科癌症的个体化治疗。
Mol Diagn Ther. 2014 Apr;18(2):137-51. doi: 10.1007/s40291-013-0070-3.
3
Personalized therapy in endometrial cancer: challenges and opportunities.
子宫内膜癌的个体化治疗:挑战与机遇。
Cancer Biol Ther. 2012 Jan 1;13(1):1-13. doi: 10.4161/cbt.13.1.18438.
4
The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas.子宫内膜癌中 CerbB2 表达与雌激素受体、孕激素受体及预后参数的关系。
Diagn Pathol. 2010 Feb 18;5:13. doi: 10.1186/1746-1596-5-13.
5
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.拉帕替尼(一种新型HER2和EGFR双激酶抑制剂)在人子宫内膜癌细胞中的活性。
Br J Cancer. 2008 Mar 25;98(6):1076-84. doi: 10.1038/sj.bjc.6604278. Epub 2008 Mar 11.
6
Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome.子宫内膜癌:免疫组化检测的增殖指数是长期预后的预测指标。
J Clin Pathol. 1998 Jan;51(1):25-9. doi: 10.1136/jcp.51.1.25.